Peficitinib

Peficitinib is a medication used to treat moderate to severe rheumatoid arthritis. It is classified as a Janus kinase inhibitor, and works by blocking a certain type of enzyme in the body that can cause inflammation. Peficitinib is taken orally, usually once daily. Common side effects include nausea, diarrhea, and abdominal pain.

Peficitinib, brand name Smyraf, is a medication used to treat moderate-to-severe rheumatoid arthritis in adults who have not responded well to other treatments. Here's a breakdown of some key points:

• Category: Peficitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors.
• How it works: JAK inhibitors work by blocking certain enzymes in the body's immune system that contribute to inflammation and joint damage in rheumatoid arthritis.
• Approval: Peficitinib is currently approved for use in Japan, Korea, and Taiwan. It is undergoing further development in other regions.

Here are some additional details about Peficitinib:

• Efficacy: Studies have shown that Peficitinib can be effective in improving symptoms of rheumatoid arthritis, such as pain, stiffness, and swelling in the joints.
• Safety: Peficitinib appears to have a similar safety profile to other JAK inhibitors. Common side effects can include upper respiratory infections, shingles, and elevated liver enzymes. Like all medications, there are also potential risks and interactions to consider, so it's important to talk to a doctor about whether Peficitinib is right for you.